635-41-6

Basic information

• Product Name: trimetozine
• Synonyms: Abbott-22370;NSC-62939;PS 2383;PS-2383;morpholin-4-yl-(3,4,5-trimethoxyphenyl)methanone;morpholino-(3,4,5-trimethoxyphenyl)methanone;4-(3,4,5-TriMethoxybenzoyl)tetrahydro-1,4-oxazine;4-Morpholinyl(3,4,5-triMethoxyphenyl)Methanone
• CAS NO: 635-41-6
• Molecular Formula: C₁₄H₁₉NO₅
• Molecular Weight: 281.306
• EINECS: 211-236-0
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Neurochemicals;Pharmaceuticals
• Mol File: 635-41-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 120-122°
• Boiling Point: 423.97°C (rough estimate)
• Flash Point: 232.9°C
• Appearance: /
• Density: 1.1755 (rough estimate)
• Vapor Pressure: 1.07E-08mmHg at 25°C
• Refractive Index: 1.5230 (estimate)
• PKA: -1.60±0.20(Predicted)
• CAS DataBase Reference: trimetozine(CAS DataBase Reference)
• NIST Chemistry Reference: trimetozine(635-41-6)
• EPA Substance Registry System: trimetozine(635-41-6)

Safety Data

• Hazardous Substances Data: 635-41-6(Hazardous Substances Data)

Usage

Description

Trimetozine is a chemical compound with a variety of applications in different industries. It is known for its sedative and mild tranquilizing effects, making it useful in the treatment of anxiety. Additionally, it serves as a metabolite of the antisecretory and antiulcer drug Trithiozine.

Uses

Used in Pharmaceutical Industry:
Trimetozine is used as a sedative and tranquilizer for its mild tranquilizing effects in the treatment of anxiety.
Used in Urology:
Trimetozine is used as an antiurolithic agent to prevent the formation of kidney stones.
Used in Cosmetics Industry:
Trimetozine is used as a depigmentation agent to reduce skin pigmentation and even out skin tone.
Used in Radiation Protection:
Trimetozine is used as a radiation protectant to protect the skin and other tissues from the harmful effects of radiation exposure.

Originator

Opalene,Theraplix,France,1966

Manufacturing Process

46 g 3,4,5-trimethoxybenzoyl chloride are dissolved in 300 ml anhydrous benzene and 25 g triethylamine and thereafter 19 g anhydrous morpholine are added in small portions with ice-cooling. The solution is boiled for 2 hours under reflux. The precipitate is filtered off, and the solution is washed with dilute sulfuric acid, then with sodium hydrogen carbonate solution and finally with water, and then evaporated. The residual yellow oil soon crystallizes; the crystalline mass of the desired material is taken up with ether, filtered and then recrystallized from 90% ethanol, from which it separates in prisms. It is slightly soluble in water. Yield: 80%. melting point 120°C to 122°C.

Therapeutic Function

Sedative

InChI:InChI=1/C14H19NO5/c1-17-11-8-10(9-12(18-2)13(11)19-3)14(16)15-4-6-20-7-5-15/h8-9H,4-7H2,1-3H3

Upstream product

• 110-91-8 morpholine 
• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 25245-29-8 5-iodo-1,2,3-trimethoxybenzene 
• 201230-82-2 carbon monoxide 
• 118-41-2 Eudesmic acid 
• 35619-65-9 tritiozine 
• 4521-61-3 3,4,5-Trimethoxybenzoyl chloride 

Downstream Products

• 35619-65-9 tritiozine 
• 889130-03-4 methyl (E)-3-(3,4,5-trimethoxyphenyl)-3-(dimethyl(phenyl)silyl)acrylate 
• 266329-23-1 (dimethylphenylsilyl)(3,4,5-trimethoxyphenyl)methanone 

Relevant articles and documents

In situ protection and deprotection of amines for iron catalyzed oxidative amidation of aldehydes

An environmentally friendly synthetic route by the application of CO2 to synthesize amides via in situ protection and deprotection of amines for iron catalyzed oxidative amidation of aldehydes was developed. Various secondary and tertiary amides have been synthesized in moderate to good yields under mild and neutral reaction conditions. The use of amine hydrochloride salts and hence base for neutralization step is totally avoided in this protocol.

Silica gel-mediated amide bond formation: An environmentally benign method for liquid-phase synthesis and cytotoxic activities of amides

An efficient, functional group tolerable, and environmentally benign process for the synthesis of amides was developed. No activation reagents or scavengers are required in this process. Purification of desired compounds is easy, rapid, and cost-effective. This protocol provides an alternative for the combinatorial liquid-phase synthesis of amide libraries for drug discovery. By this method, a number of amides were prepared and evaluated in vitro against a panel of human tumor cell lines. Cinnamic amide IV-4 was found to be the most potent compound synthesized against four human tumor cell lines.

Chiral silanes via asymmetric hydrosilylation with catalytic CuH

CuH-catalyzed asymmetric conjugate reduction of β-silyl-α, β-unsaturated esters has been developed. Using PMHS as a stoichiometric source of hydride and in situ generated CuH ligated by Solvias' JOSIPHOS analogue PPF-P(t-Bu)2 leads to highly enantioselective 1,4-reductions.